Characterizing Difficulty and Life Disruption During B-Acute Lymphoblastic Leukemia Therapy From the Perspective of

Kellee N Parker1, Sarah W Alexander2, Lisa M Jacola3

  • 1Department of Pediatrics, University of Utah, Salt Lake City, Utah, USA.

Pediatric Blood & Cancer
|September 9, 2025
PubMed

Insights

Parents find childhood B-acute lymphoblastic leukemia (B-ALL) treatment difficult due to side effects like nausea and vomiting, and care aspects like hospital visits. Understanding these challenges is key to improving pediatric cancer care.

Area of Science:

  • Pediatric Oncology
  • Childhood Cancer Survivorship
  • Patient-Reported Outcomes

Background:

  • Childhood B-acute lymphoblastic leukemia (B-ALL) treatment is lengthy and toxic, despite high cure rates in developed settings.
  • Understanding parental perspectives on treatment burdens is crucial for enhancing pediatric cancer care.
  • Previous research has not fully captured the specific difficulties parents face during B-ALL treatment.

Purpose of the Study:

  • To identify child side effects, chemotherapeutic agents, and care aspects parents perceive as most difficult or disruptive during B-ALL treatment.
  • To explore variations in these perceptions based on child or parent characteristics.
  • To inform future improvements in B-ALL treatment regimens and supportive care.

Main Methods:

  • An online survey was administered to parents of children (aged 1-19 years) diagnosed with B-ALL.
  • Participants were members of the Momcology pediatric cancer support and advocacy organization.
  • Data were analyzed descriptively, with inferential statistics used to examine characteristic-based differences.

Main Results:

  • Nausea/vomiting, decreased energy, and neuropathy were common difficult side effects during pre-maintenance therapy.
  • Mood changes were the most difficult side effect during maintenance therapy.
  • Oral corticosteroids, unplanned hospital visits, and compromised immunity were rated as the most difficult/disruptive aspects of care.

Conclusions:

  • Treatment for childhood B-ALL imposes significant difficulties on children and their families.
  • Parent-reported challenges highlight critical areas for optimizing treatment protocols and supportive care strategies.
  • Addressing treatment-related toxicities and logistical burdens is essential for improving the quality of life for children with B-ALL.
Abstract